Synthesis, ligand binding, and QSAR (CoMFA and classical) study of 3 beta-(3'-substituted phenyl)-, 3 beta-(4'-substituted phenyl)-, and 3 beta-(3',4'-disubstituted phenyl)tropane-2 beta-carboxylic acid methyl esters. 1994

F I Carroll, and S W Mascarella, and M A Kuzemko, and Y Gao, and P Abraham, and A H Lewin, and J W Boja, and M J Kuhar
Chemistry and Life Sciences, Research Triangle Institute, North Carolina 27709.

Several new 3 beta-(4'-substituted phenyl)-, 3-beta-(3'-substituted phenyl)-, and 3 beta-(3',4'-disubstituted phenyl)tropane-2 beta-carboxylic acid methyl esters were prepared and assayed for inhibition of [3H]WIN 35,428 binding to the dopamine transporter. The 3 beta-(3',4'-dichloro) and 3 beta-(4'-chloro-3'-methyl) analogues (2w and 2y; RTI-111 and RTI-112, respectively) with IC50 values of 0.79 and 0.81 nM showed the highest affinity. The contributions of quantitative structure-activity relationship (QSAR) models derived from the classical and comparative molecular field analysis (CoMFA) approaches to rational drug design were examined. CoMFA models were derived using steric and electrostatic potentials with SYBYL default values while the classical models were derived from pi and MR parameters. Using a 12-compound training set, both models were used for predicting the binding affinity of compounds both inside and outside the training set. The CoMFA study provided new insight into the steric and electrostatic factors influencing binding to the DA transporter and provided additional support for our original finding that CoMFA is useful in predicting and designing new compounds for study. The classical QSAR models, which were easier to obtain, suggest that the distribution property (pi) of the compounds is an important factor. Overall, the SAR, CoMFA, and conventional QSAR studies elaborated some features of the cocaine binding site pharmacophore and provided useful predictive information.

UI MeSH Term Description Entries
D008297 Male Males
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D008956 Models, Chemical Theoretical representations that simulate the behavior or activity of chemical processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment. Chemical Models,Chemical Model,Model, Chemical
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D003042 Cocaine An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake. Cocaine HCl,Cocaine Hydrochloride,HCl, Cocaine,Hydrochloride, Cocaine

Related Publications

F I Carroll, and S W Mascarella, and M A Kuzemko, and Y Gao, and P Abraham, and A H Lewin, and J W Boja, and M J Kuhar
September 1991, Journal of medicinal chemistry,
F I Carroll, and S W Mascarella, and M A Kuzemko, and Y Gao, and P Abraham, and A H Lewin, and J W Boja, and M J Kuhar
April 2005, Journal of medicinal chemistry,
F I Carroll, and S W Mascarella, and M A Kuzemko, and Y Gao, and P Abraham, and A H Lewin, and J W Boja, and M J Kuhar
October 1996, Journal of medicinal chemistry,
F I Carroll, and S W Mascarella, and M A Kuzemko, and Y Gao, and P Abraham, and A H Lewin, and J W Boja, and M J Kuhar
December 2004, Journal of medicinal chemistry,
F I Carroll, and S W Mascarella, and M A Kuzemko, and Y Gao, and P Abraham, and A H Lewin, and J W Boja, and M J Kuhar
April 1987, Journal of medicinal chemistry,
F I Carroll, and S W Mascarella, and M A Kuzemko, and Y Gao, and P Abraham, and A H Lewin, and J W Boja, and M J Kuhar
April 1994, Journal of medicinal chemistry,
F I Carroll, and S W Mascarella, and M A Kuzemko, and Y Gao, and P Abraham, and A H Lewin, and J W Boja, and M J Kuhar
November 2000, Bioorganic & medicinal chemistry letters,
F I Carroll, and S W Mascarella, and M A Kuzemko, and Y Gao, and P Abraham, and A H Lewin, and J W Boja, and M J Kuhar
September 1996, Journal of medicinal chemistry,
F I Carroll, and S W Mascarella, and M A Kuzemko, and Y Gao, and P Abraham, and A H Lewin, and J W Boja, and M J Kuhar
August 2002, Journal of medicinal chemistry,
F I Carroll, and S W Mascarella, and M A Kuzemko, and Y Gao, and P Abraham, and A H Lewin, and J W Boja, and M J Kuhar
June 1992, Journal of medicinal chemistry,
Copied contents to your clipboard!